| Daraxonrasib core (acrylic warhead scaffold)Abstract pharmacophoredaraxonrasib-corePage | Scaffold | C=CC(=O)Nc1ccc(F)cc1 | — | — | KRAS G12C · covalent · core · Parent acrylicamide hinge-binding motif shared across the series. |
| DaraxonrasibKnown compounddaraxonrasibPage | Drug | C[C@H]1CN(C(=O)C2=C(NC3=CC=CC(F)=C3)N=C(N2… | Daraxonrasib core (acrylic warhead scaffold) | 16%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | clinical · KRAS G12C · Reference clinical inhibitor; mapping center for this scaffold family. |
| Daraxon lead compound 1Exploratory analogdaraxon-lead-1Page | Derivative | C=CC(=O)Nc1ccc(F)cc1NC1=CC=CC=C1 | Daraxonrasib analog 01 | 51%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | lead · preclinical · Preclinical lead. Derived analog of parent node in Daraxonrasib scaffold family. |
| Daraxon lead compound 2Exploratory analogdaraxon-lead-2Page | Derivative | C=CC(=O)Nc1ccc(F)cc1NC1=CC=C(F)C=C1 | Daraxon lead compound 1 | 63%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | lead · SAR / analog node exploring potency, selectivity, or ADME. |
| Daraxonrasib analog 01Exploratory analog (rule-generated)daraxonrasib-analog-01Page | Derivative | C=CC(=O)Nc1ccc(F)c(F)c1 | Daraxonrasib core (acrylic warhead scaffold) | 65%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | F-scan · Fluorine walk on solvent-exposed aryl. |
| Daraxonrasib analog 02Exploratory analog (rule-generated)daraxonrasib-analog-02Page | Derivative | C=CC(=O)Nc1ccc(Cl)cc1 | Daraxonrasib analog 01 | 66%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | ADME · SAR / analog node exploring potency, selectivity, or ADME. |
| Daraxonrasib analog 03 (warhead methyl)Exploratory analog (rule-generated)daraxonrasib-analog-03Page | Derivative | C=CC(=O)Nc1ccc(F)cc1C | Daraxonrasib core (acrylic warhead scaffold) | 54%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | SAR · SAR exploration node. Derived analog of parent node in Daraxonrasib scaffold family. |
| Dara-P1 (ADC payload)Payloaddaraxon-payload-p1Page | Payload | C=CC(=O)Nc1ccc(F)cc1NC(=O)CCN | Daraxonrasib core (acrylic warhead scaffold) | 45%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | ADC · payload · cleavable · Payload variant retaining core hinge binder; cleavable handle at C4. |
| Dara-P2 (ADC payload)Payloaddaraxon-payload-p2Page | Payload | C=CC(=O)Nc1ccc(F)cc1NC(=O)CCNC(=O)C | Dara-P1 (ADC payload) | 41%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | ADC · payload · ADC platform member. Released warhead after lysosomal cleavage. |
| Dara-P3 (next-gen payload)Payloaddaraxon-payload-p3Page | Payload | C=CC(=O)Nc1ccc(F)cc1NC(=O)CCNC(=O)CCN | Dara-P2 (ADC payload) | 40%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | payload · ADC · ADC platform member. Released warhead after lysosomal cleavage. |
| Mc-VC-PABCLinkermc-vc-pabcPage | Linker | CC(C)C[C@H](NC(=O)[C@H](CCCNC(=O)OCc1ccccc… | Daraxonrasib core (acrylic warhead scaffold) | 10%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | linker · cleavable · Cathepsin-cleavable dipeptide linker. |
| SMCCLinkersmccPage | Linker | O=C(C=C)NCCCC[C@@H]1NC(=O)CNC1 | Daraxonrasib core (acrylic warhead scaffold) | 22%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | linker · non-cleavable · Linker for antibody conjugation. Connects antibody to payload; cleavage chemistry defines … |
| Sulfo-SPDBLinkersulfo-spdbPage | Linker | O=C(CCCC[C@@H]1NC(=O)CNC1)SSCC(=O)N | Daraxonrasib core (acrylic warhead scaffold) | 7%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | linker · cleavable · Linker for antibody conjugation. Connects antibody to payload; cleavage chemistry defines … |
| ADC-Dara-101ADCadc-dara-101Page | ADC | C=CC(=O)Nc1ccc(F)cc1NC(=O)CCNC(=O)C | Dara-P2 (ADC payload) | 41%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | ADC · preclinical · Antibody-drug conjugate construct; displayed structure is the payload warhead (ADC-Dara-10… |
| ADC-Dara-102ADCadc-dara-102Page | ADC | C=CC(=O)Nc1ccc(F)cc1NC(=O)CCN | Dara-P1 (ADC payload) | 45%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | ADC · Antibody-drug conjugate construct; displayed structure is the payload warhead (ADC-Dara-10… |